VBI Vaccines (NASDAQ:VBIV) Earns Sell Rating from Analysts at StockNews.com

Analysts at StockNews.com began coverage on shares of VBI Vaccines (NASDAQ:VBIV) in a research note issued to investors on Wednesday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

VBI Vaccines Price Performance

VBIV opened at $0.12 on Wednesday. VBI Vaccines has a 52-week low of $0.11 and a 52-week high of $1.35. The business’s fifty day moving average is $0.62 and its 200-day moving average is $0.62.

VBI Vaccines (NASDAQ:VBIV) last announced its quarterly earnings data on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). The firm had revenue of $1.21 million for the quarter, compared to analyst estimates of $2.85 million. VBI Vaccines had a negative return on equity of 525.42% and a negative net margin of 881.79%. On average, research analysts expect that VBI Vaccines will post -1.23 earnings per share for the current year.

About VBI Vaccines

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.